MXPA02001340A - Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos. - Google Patents

Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.

Info

Publication number
MXPA02001340A
MXPA02001340A MXPA02001340A MXPA02001340A MXPA02001340A MX PA02001340 A MXPA02001340 A MX PA02001340A MX PA02001340 A MXPA02001340 A MX PA02001340A MX PA02001340 A MXPA02001340 A MX PA02001340A MX PA02001340 A MXPA02001340 A MX PA02001340A
Authority
MX
Mexico
Prior art keywords
compounds
novel
derivatives
formula
benzodiazepine compounds
Prior art date
Application number
MXPA02001340A
Other languages
English (en)
Spanish (es)
Inventor
Hossien Pajouhesh
Original Assignee
Prescient Neuropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prescient Neuropharma Inc filed Critical Prescient Neuropharma Inc
Publication of MXPA02001340A publication Critical patent/MXPA02001340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02001340A 1999-08-05 2000-08-04 Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos. MXPA02001340A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2279689 1999-08-05
CA2299477 2000-02-24
PCT/CA2000/000897 WO2001010846A2 (en) 1999-08-05 2000-08-04 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system

Publications (1)

Publication Number Publication Date
MXPA02001340A true MXPA02001340A (es) 2004-07-16

Family

ID=25681103

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001340A MXPA02001340A (es) 1999-08-05 2000-08-04 Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.

Country Status (5)

Country Link
EP (1) EP1210338A2 (ja)
JP (1) JP2003506440A (ja)
AU (1) AU6420700A (ja)
MX (1) MXPA02001340A (ja)
WO (1) WO2001010846A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339968T1 (de) * 2001-04-02 2006-10-15 Univ Brown Res Found Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
WO2002083665A1 (en) * 2001-04-12 2002-10-24 F. Hoffmann-La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
DK1379511T3 (da) * 2001-04-12 2005-11-07 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ATE519751T1 (de) 2007-04-19 2011-08-15 Hoffmann La Roche Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
EA017249B8 (ru) 2007-05-10 2013-01-30 Олбани Молекьюлар Рисерч, Инк. Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
ES2356032T3 (es) 2007-09-14 2011-04-04 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas.
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
CN112574220B (zh) * 2020-12-08 2022-10-11 北京工业大学 一种手性杂环化合物及制备方法
CN112851691B (zh) * 2021-01-27 2022-10-11 北京工业大学 一种手性噁二嗪杂环类化合物及制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH554349A (de) * 1971-03-17 1974-09-30 Crc Ricerca Chim Verfahren zur herstellung von optisch aktiven 1,3-dihydro-2h-1,4-benzodiazepin-2-onen.
US3915961A (en) * 1972-12-21 1975-10-28 American Home Prod 5-Aryl-1H-1,4-benzodiazepine-2(3H)-one-3-phosphonic acids, derivatives and processes for their use
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
DE3751673T2 (de) * 1986-10-24 1996-08-01 Abbott Lab Test, Indikatoren, Immunogene und Antikörper für Benzodiazepine
IL96613A0 (en) * 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
DE4000768A1 (de) * 1990-01-12 1991-07-18 Bayer Ag Hydrate des 7-chlor-5-phenyl-spiro(1h-1,4-benzodiazepin-3,4'-piperidin)-2(3h)-on-hydrochlorids
JPH04202186A (ja) * 1990-11-30 1992-07-22 Dainabotsuto Kk １―または、３―置換クロナゼパム誘導体
WO1993019052A1 (en) * 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
GB2282594A (en) * 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
KR20000069654A (ko) * 1996-12-23 2000-11-25 엘란 파마슈티칼스, 인크. 시클로알킬, 락탐, 락톤 및 관련 화합물, 그의 약제학적 조성물및 그를 사용한 β-아밀로이드 펩티드의 방출 및(또는) 합성억제 방법
HRP980093A2 (en) * 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
CN1554649A (zh) * 1997-11-21 2004-12-15 NPSҩ�����޹�˾ 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines

Also Published As

Publication number Publication date
AU6420700A (en) 2001-03-05
EP1210338A2 (en) 2002-06-05
JP2003506440A (ja) 2003-02-18
WO2001010846A2 (en) 2001-02-15
WO2001010846A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
MXPA02011053A (es) Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
AU1383297A (en) Novel n-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
MX9707453A (es) Derivados de quinazolina.
MXPA02010405A (es) Derivados de aminocarboxialquilo novedosos de acido barbiturico.
TW430662B (en) Benzene-condensed hetero ring derivatives and their uses
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
MX9706605A (es) Derivados de indol como antagonistas de los aminoacidos exitadores.
AU6611696A (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
AU8361198A (en) Novel compounds
AU4629796A (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
MXPA02000242A (es) Analogos de 2-aminoindano.
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2001002340A3 (en) Novel aminoindanes
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
BG102229A (en) Endothelium receptor antagonists
AU5334196A (en) Method for the preparation of esters of anhydroecgonine
AU5662996A (en) Compounds and compositions for delivering active agents
MX9804631A (es) Antagonistas quinazolin-4-ona del ampa.
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.
MX9801192A (es) Nuevos peptidos opioides.